Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-derived cytokine enhances bitter sensing through remote control of bitter taste neurons via the Upd3/Spz5/Toll-6 axis in <i>Drosophila</i>.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis.

Molecular cancer·2026
Same author

AI-Based Detection of Proximal Caries Across Radiographic Modalities: A Systematic Review and Meta-Analysis.

Dento maxillo facial radiology·2026
Same author

Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer.

Nature communications·2026
Same author

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Blood cancer discovery·2026
Same author

Can Healthy Diet Buffer the Impact of Adverse Social Determinants on HPV Infection? Evidence From NHANES 2005-2016.

The journal of obstetrics and gynaecology research·2026

Related Experiment Video

Updated: Oct 19, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.0K

Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma.

Wei Qin1, Di Fu1, Qing Shi1

  • 1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in Oncology
|September 24, 2021
PubMed
Summary

Localized diffuse large B-cell lymphoma (DLBCL) with single nodal or extranodal involvement shows distinct molecular features but similar survival outcomes. Personalized treatment strategies may benefit from considering specific genetic and microenvironmental factors.

Keywords:
diffuse large B-cell lymphomagene mutationsserum lactate dehydrogenasesingle extranodalsingle nodaltumor microenvironment

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.8K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K

Related Experiment Videos

Last Updated: Oct 19, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.0K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.8K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Localized diffuse large B-cell lymphoma (DLBCL) subtypes with single nodal (SN) or single extranodal (SE) involvement require further characterization in the rituximab era.
  • Understanding the clinical and molecular differences between SN and SE DLBCL is crucial for optimizing patient management.

Purpose of the Study:

  • To elucidate the clinical, molecular, and immunophenotypic characteristics of localized DLBCL with SN versus SE involvement.
  • To identify prognostic factors influencing progression-free survival (PFS) and overall survival (OS) in this patient population.

Main Methods:

  • Retrospective analysis of 181 patients and a phase 3 trial (NHL-001) of 108 patients with localized DLBCL.
  • Comprehensive genomic profiling (DNA/RNA sequencing) and immunophenotyping on subsets of patients to assess genetic aberrations, gene expression, and tumor microenvironment.

Main Results:

  • SE patients exhibited a higher proportion of low-intermediate risk by National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI).
  • SN DLBCL showed increased MPEG1 mutations, while SE DLBCL displayed TGF-β pathway activation and suppressed T-cell receptor signaling, indicating an immunosuppressive microenvironment.
  • Extranodal involvement did not impact PFS or OS; elevated serum lactate dehydrogenase and ATM mutations were adverse prognostic factors for OS and PFS, respectively.

Conclusions:

  • Localized DLBCL with SN or SE involvement has distinct molecular profiles but comparable survival outcomes.
  • Prognosis is generally favorable, but specific clinical, genetic, and immune microenvironment factors warrant consideration for personalized therapeutic approaches.